Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Using Vaccines to Bolster Immunotherapy Responses in Kidney Cancer

January 28th 2017

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.

Immunotherapy Data is Encouraging in Kidney Cancer

January 26th 2017

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

Combination Therapy Is Promising for Kidney Cancer, Expert Says

January 21st 2017

David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.

Changing the Frontline Treatment of Kidney Cancer

January 12th 2017

After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.

New Agents Are Shifting Kidney Cancer Treatment Strategies

December 19th 2016

Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.

Size Matters: Examining Obesity's Role in Cancer Outcomes

December 14th 2016

Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.

Expert Discusses Immunotherapy Combos in Kidney Cancer

December 5th 2016

Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.

What's Next in Immunotherapy?

December 3rd 2016

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

Experts Discuss Immunotherapy's Role in the Shifting Landscape in Solid Tumors

November 30th 2016

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

TKIs Will Continue to Shape Kidney Cancer Treatment

November 28th 2016

TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.

TKI Inhibitor Improves Survival in Metastatic Kidney Cancer

November 17th 2016

Cabometyx was proved to be superior to Sutent, reducing rates of disease progression or death for patients with metastatic RCC, according to a recent trial.

Cabometyx Bests Sutent in Reducing Risk of Progression or Death in Metastatic Kidney Cancer

October 11th 2016

In a recent phase 2 trial, Cabometyx showed longer progression-free survival than Sutent in patients with metastatic kidney cancer.

Expert: We're Approaching the Golden Age in Kidney Cancer Care

October 9th 2016

After going through the "Dark Ages," we're approaching the "Golden Age" of kidney cancer care, with more options available than ever, says James Hsieh.

8 Questions With a Physician: Immunotherapy in Genitourinary Cancers

October 3rd 2016

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

A Sign of the Times: The Changing Treatment Landscape for Advanced Kidney Cancer

September 23rd 2016

The treatment landscape for advanced kidney cancer has changed dramatically over the past few years, with several targeted drugs and an immunotherapy approved by the FDA.

Prioritizing Clinical Trials Led to New Therapies for Kidney Cancer

September 23rd 2016

Ten years ago, patients with advanced RCC had very few treatment options, yet today, there are multiple therapeutic strategies and more in the pipeline for this not-very-common tumor type, writes our editor-in-chief, Debu Tripathy.

Expert Highlights Progress, Looks Ahead in Kidney Cancer Care

September 21st 2016

While many new treatment options have been introduced for kidney cancer in recent years, the question of how to sequence them is still being debated.

High Body Mass Index Associated With Improved Survival in Kidney Cancer

September 16th 2016

A recent study showed a correlation between higher body mass index and survival in some patients with kidney cancer.

Kidney Cancer Association Strives to Bridge Gaps in Knowledge

September 14th 2016

Most people don't know much about kidney cancer at the time of their diagnosis. The Kidney Cancer Association wants to change that.

4 Questions With an Expert: Cabometyx and the Future of Kidney Cancer Care

August 15th 2016

Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.

Expert Discusses Changing Field of Immunotherapy to Treat Genitourinary Cancers

August 13th 2016

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

Sutent Extends Disease-Free Survival in Kidney Cancer

August 4th 2016

A recent phase 3 study showed that Sutent extended disease-free survival for patients with renal cell carcinoma.

Reviewing a New Treatment Combination for Advanced Kidney Cancer

July 6th 2016

Sumanta K. Pal weighs in on a new drug combination that is showing promise for patients with RCC who progressed on Cabometyx (cabozantinib) and Opdivo (nivolumab).

The Exciting Present and Future of Kidney Cancer Care

June 24th 2016

The treatment paradigm in renal cell carcinoma (RCC) has expanded over recent months to include three practice-changing agents in the second-line setting.

Expert Discusses What's Next for Opdivo in Kidney Cancer

June 22nd 2016

Not only is Opdivo changing the way RCC is being treated, but the immunotherapy is also here to stay, according to David F. McDermott.

Cabometyx Improves Survival in Renal Cell Carcinoma

June 10th 2016

Previously treated patients with advanced renal cell carcinoma saw a higher overall survival rate with Cabometyx when compared to those on Afinitor, according to a phase 3 study.

Effectiveness of Opdivo Persists Long-Term in Advanced Renal Cell Carcinoma

June 6th 2016

In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.

Exploring the Next Steps for Immunotherapy in Kidney Cancer

June 3rd 2016

What are the next steps for immunotherapy in RCC? CURE spoke with Mark Ball to find out.

Lenvima and Afinitor Approved for Advanced Renal Cell Carcinoma

May 14th 2016

After a phase 2 study, Lenvima and Afinitor gained FDA approval for the treatment of renal cell carcinoma.

Novel Drug Combination Shows Promise in Small, Early Phase Study of Kidney Cancer

May 9th 2016

“This is a small-site, single-arm study, but these preliminary data are encouraging,” says lead study author Roberto Pili. “It suggests that this combination of an HDAC inhibitor can induce a greater benefit with an immunotherapy — in this case, IL-2.”